Jenna Philpott

Novo Holdings and Jeito Capital co-led the $85m round. Credit: Sergey Khakimullin via Getty Images. Belgium-based biotech Augustine Therapeutics has raised €78m ($85m) in funding to support the development of its lead candidate as it enters a Phase I/II trial […]

ATTR-CM is a potentially fatal disease of the heart muscle. Credit: urbazon via Getty Images. Alnylam Pharmaceutical’s has secured US Food and Drug Administration (FDA) approval for Amvuttra (vutrisiran), expanding its use to treat transthyretin amyloid cardiomyopathy (ATTR-CM), a rare

J&J has begun construction of a biologics site in North Carolina, US. Credit: Cristina Arias via Getty Images. Johnson & Johnson Innovative Medicine (J&J) is significantly expanding its US footprint with a $55bn investment over the next four years, as

CTS New England is taking place in Boston, Massachusetts, on 8–9 April. Credit: DenisTangneyJr via Getty Images. As the clinical trial landscape evolves with a growing demand for efficiency, flexibility, and innovation in 2025, experts will gather to discuss how

AstraZeneca’s Krishna Bulusu presented at the ELRIG Drug Discovery conference in London on 11 March. Credit: SOPA Images via Getty Images. Artificial intelligence (AI) is transforming drug discovery, but its implementation must be thoughtful and strategic, according to Krishna Bulusu,

Hologen’s AI models have already been used to analyse data from MeiraGTx’s clinical trials. Credit: innni via Getty Images. MeiraGTx has struck a deal with Hologen Limited, an artificial intelligence (AI) company specialising in multimodal generative AI models, to advance

Endometriosis can cause severe pain, heavy periods, fatigue, and fertility issues. Credit: LaylaBird via Getty Images. The UK’s National Institute for Health and Care (NICE) has approved Gedeon Richter’s Ryeqo (relugolix–estradiol–norethisterone), a once-daily oral treatment for endometriosis, for use on

The combined company is expected to be listed on the New York Stock Exchange. Credit: Anton Vierietin via Getty Images. Mallinckrodt Pharmaceuticals and Endo have agreed to merge in a $6.7bn deal, combining two pharmaceutical companies that recently emerged from

Orphelia said it will continue to make Kizfizo available to paediatric patients under certain programmes and clinical trials. Credit: Andrii Yalanskyi via Getty Images. Orphelia Pharma is exploring alternative regulatory pathways for Kizfizo (temozolomide) following a negative opinion from the

Zealand first announced that it was seeking a development partner in August 2024. Credit: Liudmila Chernetska via Getty Images. Zealand Pharma has named Roche as a development and commercialisation partner for its lead obesity candidate petrelintide, after a seven-month search.